The Academy of Pharmaceutical Sciences
'Promoting the pharmaceutical sciences'


AbbVie seeks US approval for psoriasis drug risankizumab.....           Corvidia Therapeutics raises $60m funding to speed up clinical work.....           ADC Therapeutics terminates ADCT-502 program targeting HER2 expressing solid tumors.....           ValiRx secures EU patent grant for VAL201 prostate cancer treatment.....           AstraZeneca's Farxiga campaign plays on 'F-words' for fresh and fun engagement.....           McCann Health's new scientific council offers agency and science brainpower all in one place.....           Shire and Takeda come to terms with a $64B deal, the biggest pharma M&A in years.....           What's your Aimovig rollout plan, Amgen? Growth-hungry investors want to know.....           Feds almost ready to charge drugmakers?and executives?in generics price-fixing probe.....           Look at our new launches, GSK urges, as its respiratory woes steal the limelight.....           Shire considers Takeda's revised £46bn takeover offer.....           AstraZeneca?s lung cancer combo fails in phase III trial.....           FDA expands GSK?s Trelegy Ellipta indication in COPD.....           Lilly?s strong Q1 cushions the blow of FDA thumbs-down on high-dose baricitinib.....           Pfizer's Trumenba just got closer to a new FDA nod. Can it catch up to GlaxoSmithKline's Bexsero?.....           Pernix and company ink $75M deal to put Orexigen out of its misery.....           In a digital first for pharma, Novartis signs on to market Pear's drug-abuse therapies.....           Fifth and final bid? A determined Takeda said to be nearing $60B-plus Shire deal.....           Don't panic about Spinraza's slowdown, Biogen executives say. It's got plenty of room to grow.....           Lilly?s strong Q1 cushions the blow of FDA thumbs-down on high-dose baricitinib.....           It's another fail for AstraZeneca's I-O combo, but it may not mean what you think.....           Pernix and company ink $75M deal to put Orexigen out of its misery.....           In a blow for pharma, Supreme Court upholds the hated IPR patent challenge.....           Pfizer biosimilar of Roche's cancer drug fails to get FDA approval.....           Scientists develop new method to make drugs smarter.....           Celgene expands bispecific antibody collaboration with Zymeworks.....           Prothena scraps development of AL amyloidosis drug.....           Illumina Reports Financial Results for First Quarter of Fiscal Year 2018.....           Boehringer Ingelheim expands adherence-improving respiratory rewards program.....           Pfizer's first U.K. ads for OTC Viagra put erectile dysfunction in perspective.....           Squeezed Mylan axing 500 jobs in West Virginia to 'right-size' massive plant.....           FDA to Pfizer: To win OK for Herceptin biosimilar, fork over more 'technical' info.....           Fresenius dumps its $4.3B Akorn buyout, and a 'legal battle royale' could come next.....           Fresenius Kabi scraps $4.3bn merger with US generic drugmaker Akorn.....           Synpromics to partner with Lonza to improve biopharmaceuticals manufacturing.....           Alnylam signs settlement agreement with Dicerna to resolve trade secret misappropriation claims.....           Biogen to pay Ionis $1bn for neurological drugs development.....           After some Thursday drama, Shire weighs Takeda's cash-sweetened $61.5B offer.....           After some Thursday drama, Shire weighs Takeda's fourth buyout bid at $61B-plus.....           Good news, Glaxo: Novartis' Advair copy definitely won't see the market this year.....           FiercePharmaAsia?Tussle for Shire, Hanmi?s EGFR bail, Grail?s $1B pre-IPO round.....           Sanofi's Dengvaxia needs a dengue diagnostic, stat, thanks to WHO.....           Novartis pads case for new MS blockbuster with disease-progression analysis.....           Shire rejects $63bn takeover proposal from Takeda.....           Tmunity raises another $35m to advance T Cell therapies.....           Helperby Therapeutics? combination antibiotic therapy is effective against WHO critical priority pathogen in phase 1 study.....           Pharma ads on the brain: DTC on lifestyle sites triggers a bigger emotional punch.....           Merck KGaA, not Pfizer, lands consumer health deal with P&G worth $4.2B.....           AstraZeneca's Tagrisso just got the lung cancer nod it needs to hit $3B in sales.....           Greek lawmakers hand off probe of politicians accused of taking Novartis bribes: report.....           Allergan swoops in as Takeda's third Shire bid falls short at $61B.....           Cosentyx woes, generics weakness cast cloud on otherwise solid Q1 for Novartis.....           Allergan pulls out of Shire deal talks just hours after disclosing it was in the mix.....           Merck to sell global consumer health business to P&G for $4.2bn.....           Sandoz, Pear to commercialize prescription digital therapeutics.....           FDA approves Tagrisso as first-line treatment for EGFR-mutated non-small cell lung cancer.....           BenevolentAI raises $115m to advance AI-enabled drug development activities.....           Amid tough respiratory competition, AstraZeneca inks Symbicort outcomes-based deals.....           Lilly highlights 'relentless' women in first ads for breast cancer med Verzenio.....           Novo Nordisk tackles outcomes and affordability with pilot tying copays to adherence.....           Armed with first-ever FDA nod, Rigel preps May launch for autoimmune drug Tavalisse.....           Ultragenyx nabs blockbuster FDA nod for $200K-per-year Crysvita.....           Sanofi scouts replacement for CFO Jérôme Contamine, who's retiring after an eventful 9 years.....           How big is too big for a CEO bonus target? Annoyed Shire investors have some ideas.....           Advent in talks to buy Sanofi?s European generics business for EUR1.9bn.....           Novartis to invest $100m into antimalarials research.....           Novartis to invest $100m into antimalarials research.....           Catabasis Pharmaceuticals to reduce workforce by about 42%.....           Catabasis Pharmaceuticals to reduce workforce by about 42%.....           Roche?s Hemlibra gets FDA breakthrough status in haemophilia A without inhibitors.....           Roche?s Hemlibra gets FDA breakthrough status in haemophilia A without inhibitors.....           Merck pits its pneumococcal shot against Pfizer's mammoth Prevnar in head-to-head phase 3.....           Alliance Pharma to divest 60% stake in Unigreg.....           Alliance Pharma to divest 60% stake in Unigreg.....           Advent, near deal to buy Sanofi's Zentiva, lays out big goals for generics business.....           Roche gets double dose of good Hemlibra news with FDA breakthrough, ICER backing.....           Roche gets double dose of good Hemlibra news with FDA breakthrough, ICER backing.....           Amazon finds it's not so easy to sell drugs?and nixes one plan entirely: CNBC.....           Remicade and Xarelto woes?and Trump pricing threats?haven't stopped Johnson & Johnson hiking its 2018 forecast.....           Remicade and Xarelto woes?and Trump pricing threats?haven't stopped Johnson & Johnson hiking its 2018 forecast.....           BMS? Opdivo and Yervoy combo gets FDA approval for firstline RCC.....           Boehringer Ingelheim, Lilly, University of Oxford to study empagliflozin in chronic kidney disease.....           Alliance Pharma divests 60% stake in Unigreg.....           RSS NEWSFEED....
Welcome to
The Academy of
Pharmaceutical Sciences
 
The Academy of Pharmaceutical Sciences (APS) is the UK-based professional membership body for Pharmaceutical Scientists.

We represent individuals and organisations from around the globe, throughout their development, in the delivery of excellence in the Pharmaceutical Science sector.
 
 
Latest news

Professional recognition for Pharmaceutical Science Degrees

The Academy of Pharmaceutical Sciences (APS) is delighted to announce that the pharmaceutical science course at the University of Greenwich has become the first APS accredited course having successfully completed the accreditation process set up by the Academy towards the end of 2017.

This is the first time that a pharmaceutical science course has been accredited in the United Kingdom and it is also, we believe, a world first.

Achieving accreditation gives assurance to students and employers that the course meets the high standards required by the Academy and that these standards will be maintained throughout the 5-year period of accreditation.

APS believes that the accreditation process will raise the profile of pharmaceutical sciences in both academia and industry. The discipline is key in the discovery, development and manufacture of new medicines and as such is central to government initiatives to encourage the pharmaceutical industry to maintain and strengthen its strong base here in the UK.

The Academy will continue to work with other stakeholders to build the science base for the ultimate benefit of patients.

 
APS events overview

The APS has developed an exciting and informative programme for our events in 2018.

We are re-running the Developability Workshop and Regulatory Essentials training events which have proved enormously popular when run before.

In March, we have the first one of our collaborative meetings, 'Emerging technologies in therapeutic oligonucleotides', hosted by MedImmune, followed by 'APS Current Regulatory trends and updates in parenteral drug product development' that will be informative and interactive describing the current regulatory requirements, especially focusing on recent changes in guidelines, as well as covering topical issues, trends and developments in the wider field of parenteral products.

Don’t forget to make a note of APS@FIP, linking with the 78th FIP World Congress of Pharmacy and Pharmaceutical Science conference.

Please take a look at our programme, with event summaries, below:

Emerging technologies in therapeutic oligonucleotides
13 March 2018 - MedImmune, Cambridge
MedImmune, AstraZeneca and GE Healthcare Life Sciences, in partnership with GSK, Roche, University of Oxford, BioMax and Academy of Pharmaceutical Sciences are pleased to invite you to their sixth oligonucleotide networking event.
To learn more and to register, click here

APS Current Regulatory trends and updates in parenteral drug product development
20 - 21 March 2018 - Burleigh Court, Loughborough University
This residential course is aimed at pharmaceutical scientists and regulatory affairs professionals involved in the development, manufacture, control or registration of parenteral products. Speakers will include key industry and MHRA experts.
To learn more and to register, click here

APS Industrial Insights
26 - 27 March 2018 - Pfizer / Mylan at Discovery Park, Sandwich
EarlyBird deadline extended to midnight on Monday 5 March... register now!
An event for undergraduate and postgraduate students interested in exploring opportunities in the Pharmaceutical Industry, through a series of talks by pharmaceutical scientists working within the industry as well as a tour of the Pfizer Research and Development facilities.
To learn more and to register, click here

Accelerating paediatric formulation development
Presentation of output from SPaeDD-UK Project

28 March 2018 - Friends House, London
The Smart Paediatric Drug Development (SPaeDD) initiative co-funded by Innovate UK (the UK’s Innovation Agency) is a cross company and academic centre initiative to accelerate paediatric formulation development. The collaboration has now reached the end of its funding period and this meeting will present the final outputs from the project work streams. Each of these has produced outputs which will no doubt significantly assist the way in which medicines are developed and tested for children.
To learn more and to register, click here

APS Developability Workshop
10 - 11 April 2018 - Granta Park, Cambridge
Learn from a pharmaceutics and biopharmaceutics perspective what is required to assess a molecule in discovery and its suitability for ‘candidate selection’; determine how ‘developable’ it is with associated risk, time and cost implications; and what is needed to progress it through pre-clinical studies and into Phase 1 and 2a clinical studies to achieve Proof of Concept.
To learn more and to register, click here

APS Regulatory Essentials II
22—23 May 2018 - Burleigh Court, Loughborough University
This is a residential course aimed at pharmaceutical scientists and regulatory/quality professionals in originator and generics’ companies who will benefit from gaining a better appreciation of key elements in the development and registration of oral dosage forms.
To learn more and to register, click here

APS@FIP
7 September 2018 - Hilton Hotel, Glasgow
Linking with the 78th FIP World Congress of Pharmacy and Pharmaceutical Science conference, which will take place in the city from the 2 - 6 September 2018. The theme of this conference in 2018 is 'The Science of Differentiated Medicines'.
To learn more and to register, click here

OTHER EVENTS IN DEVELOPMENT
Developability for Biologicals
Inhaled Workshop
Basic Biopharmaceutics workshop
Nanomedicine drug delivery: Opportunities and Challenges
OrBiTo (Innovative Tools for Oral Biopharmaceutics) Conference

 
 

Reflections on APS PharmSci 2017 Conference

Date: 5 - 7 September 2017
Location: De Havilland Campus, University of Hertfordshire, Hatfield
Conference Chair: Professor Abdul Basit (University College London)
Theme: Pharmaceutical Science without Borders


A very successful 3-day conference provided an excellent interactive face to face forum for exchange of knowledge and sharing learnings and experiences in many aspects of the pharmaceutical sciences. With 80+ inspiring speakers and over 390 delegates joined together from academia, the Pharmaceutical Industry, and service companies. During the sessions, there was a steady flow of discussion which continued into the breaks and around the exhibition stands and posters.
 

Young pharmaceutical scientists had their first opportunity to present either a poster or podium presentation (or indeed both!) which is a major strength of APS PharmSci.

 

Read more, as Linda Hakes (Retiring APS Chair) and Mark McAllister (APS Chair) talk about their experiences at this year’s PharmSci.

Follow us
 
Upcoming Events
APS Regulatory Essentials II
22 - 23 May 2018
APS Nanomedicines for the Delivery of Biologics
18 July 2018
APS@FIP
7 September 2018
Job Vacancies
View all Vacancies
Advertise your job vacancies
The APS is grateful for the support of:
Join Us

Join the academy and get discounts on events, post-nominals, latest news and more.

 

The Academy of Pharmaceutical Sciences
Unit Q, Troon Way Business Centre
Humberstone Lane, Leicester, LE4 9HA
Tel: 0116 274 7351
Fax: 0116 274 7365
Email: info@apsgb.org

Terms of use:
The material included on this site is provided for information purposes only, and we make no representations or warranties as to its accuracy. Before relying on this material, you should take care to verify its accuracy, taking professional advice as appropriate.